Cargando…

Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial

The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Doo Sun, Jeong, Myung Ho, Hong, Young Joon, Kim, Ju Han, Ahn, Youngkeun, Park, Keun Ho, Hwang, Sun Ho, Kang, Dong Goo, Lee, Seung Uk, Kim, Joon Woo, Park, Jong Pil, Rhew, Jay Young, Lee, Sang Rok, Chae, Jei Keon, Yun, Kyeong Ho, Oh, Seok Kyu, Kang, Won You, Kim, Su Hyun, Cho, Jang Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chonnam National University Medical School 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794480/
https://www.ncbi.nlm.nih.gov/pubmed/29399567
http://dx.doi.org/10.4068/cmj.2018.54.1.55
_version_ 1783297132331008000
author Sim, Doo Sun
Jeong, Myung Ho
Hong, Young Joon
Kim, Ju Han
Ahn, Youngkeun
Park, Keun Ho
Hwang, Sun Ho
Kang, Dong Goo
Lee, Seung Uk
Kim, Joon Woo
Park, Jong Pil
Rhew, Jay Young
Lee, Sang Rok
Chae, Jei Keon
Yun, Kyeong Ho
Oh, Seok Kyu
Kang, Won You
Kim, Su Hyun
Cho, Jang Hyun
author_facet Sim, Doo Sun
Jeong, Myung Ho
Hong, Young Joon
Kim, Ju Han
Ahn, Youngkeun
Park, Keun Ho
Hwang, Sun Ho
Kang, Dong Goo
Lee, Seung Uk
Kim, Joon Woo
Park, Jong Pil
Rhew, Jay Young
Lee, Sang Rok
Chae, Jei Keon
Yun, Kyeong Ho
Oh, Seok Kyu
Kang, Won You
Kim, Su Hyun
Cho, Jang Hyun
author_sort Sim, Doo Sun
collection PubMed
description The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up.
format Online
Article
Text
id pubmed-5794480
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Chonnam National University Medical School
record_format MEDLINE/PubMed
spelling pubmed-57944802018-02-02 Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial Sim, Doo Sun Jeong, Myung Ho Hong, Young Joon Kim, Ju Han Ahn, Youngkeun Park, Keun Ho Hwang, Sun Ho Kang, Dong Goo Lee, Seung Uk Kim, Joon Woo Park, Jong Pil Rhew, Jay Young Lee, Sang Rok Chae, Jei Keon Yun, Kyeong Ho Oh, Seok Kyu Kang, Won You Kim, Su Hyun Cho, Jang Hyun Chonnam Med J Original Article The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up. Chonnam National University Medical School 2018-01 2018-01-25 /pmc/articles/PMC5794480/ /pubmed/29399567 http://dx.doi.org/10.4068/cmj.2018.54.1.55 Text en © Chonnam Medical Journal, 2018 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sim, Doo Sun
Jeong, Myung Ho
Hong, Young Joon
Kim, Ju Han
Ahn, Youngkeun
Park, Keun Ho
Hwang, Sun Ho
Kang, Dong Goo
Lee, Seung Uk
Kim, Joon Woo
Park, Jong Pil
Rhew, Jay Young
Lee, Sang Rok
Chae, Jei Keon
Yun, Kyeong Ho
Oh, Seok Kyu
Kang, Won You
Kim, Su Hyun
Cho, Jang Hyun
Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title_full Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title_fullStr Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title_full_unstemmed Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title_short Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
title_sort safety and efficacy of the endeavor resolute® stent in patients with multivessel disease: the heart (honam endeavor resolute) prospective, multicenter trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794480/
https://www.ncbi.nlm.nih.gov/pubmed/29399567
http://dx.doi.org/10.4068/cmj.2018.54.1.55
work_keys_str_mv AT simdoosun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT jeongmyungho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT hongyoungjoon safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT kimjuhan safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT ahnyoungkeun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT parkkeunho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT hwangsunho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT kangdonggoo safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT leeseunguk safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT kimjoonwoo safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT parkjongpil safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT rhewjayyoung safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT leesangrok safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT chaejeikeon safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT yunkyeongho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT ohseokkyu safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT kangwonyou safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT kimsuhyun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial
AT chojanghyun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial